GSK (GSK) said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of the year, having led the company through the Covid-19 pandemic, tensions with activist investor Elliott Management and a portfolio shake-up that included the spinoff of its consumer-healthcare business. Most Read from The Wall Street Journal The leadership change comes as GSK seeks to bring to market mo ...

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.Luke will succeed the current CEO, Dame Emma Walmsley.He joined GSK in 2017 and is currently Chief Commercial Officer, with worldwide responsibility for medicines and vaccines.He has been instrumental in building GSK’s specialty medicines portfolio, notably in oncology and respiratory.Luke has previously worked at senior levels in the US, Europe, and Asia, at ...

All three are near their all-time highs set a week ago. Electronic Arts climbed after the video-game maker confirmed rumors it would be taken private in what could become the largest-ever buyout funded by private-equity firms. A key economic report will arrive Friday when the government releases its monthly jobs survey.Wall Street pushed higher early Monday despite growing anxiety over a possible U.S. government shutdown later this week.Futures for the S&P 500 rose 0.5% before the bell, while futures for ...

GSK (GSK) stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year. She will be succeeded by Luke Miels, the current chief commercial officer. Prior to joining GSK in 2017, Miels has worked across the globe at AstraZeneca (AZN), Roche (RHHBY) and Sanofi (SNY). Walmsley has led GSK for nine years and says it's time to hand the reins over to someone new. "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe t ...

1. 9月29日(周一)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.42%，标普500指数期货涨0.45%，纳指期货涨 0.56%。 | = US 30 | 46,442.70 | 46,510.10 | 46,259.00 | +195.40 | +0.42% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,673.90 | 6.683.40 | 6.644.80 | +30.20 | +0.45% | | 트 US Tech 100 | 24,641.10 | 24,677.50 | 24,500.80 | +137.30 | +0.56% | 2. 截至发稿，德国DAX指数涨0.15%，英国富时100指数涨0.55%，法国CAC40指数涨0.05%，欧洲斯托克50指数涨0.06%。 | 德国DAX30 | 23,768.23 | 23,873.26 | 23,737.51 | +35.14 | +0.15% | | --- | --- | --- | --- | --- | --- | | 英国富时100 | 9,335.95 | ...

盘前市场动向 1.9月29日(周一)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.42%，标普500指数期货涨0.45%，纳指期货涨 0.56%。 黄金又双叒叕破纪录!在实现连续六周上涨后，黄金价格周一再涨1%，突破3800美元的历史新高，超越了上周二创下的峰值。 德意志银行分析师Michael Hsueh说道："黄金ETF需求如此强劲地重新回归市场，这表明存在两种针对黄金的'积极买家'行为， 一种来自中央银行，另一种来自ETF投资者。这有助于解释为何黄金的表现一直优于预期。在我们看来，美联储的宽松倾向应 会使2026年ETF持有量更有可能上升而非下降。" | = US 30 | 46.442.70 | 46,510.10 | 46,259.00 | +195.40 | +0.42% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,673.90 | 6,683.40 | 6.644.80 | +30.20 | +0.45% | | 트 US Tech 100 | 24,641.10 | 24,677.50 | 24,500.80 | +1 ...

在沃姆斯利担任葛兰素史克首席执行官期间，该公司股价累计下跌了约11%。而在宣布沃姆斯利将卸任 后，截至发稿，葛兰素史克周一美股盘前涨超3%。 沃姆斯利在其首席执行官任期内因新药研发管线问题承受了来自投资者的压力，人们担忧该公司是否有 正确的战略以实现到2031年销售额超过400亿英镑(约合540亿美元)的目标。沃姆斯利在任期内带领公司 度过了大流行，并监督推出了呼吸道合胞病毒(RSV)疫苗，同时完成了消费者健康业务的分拆，成立了 名为Haleon Plc的独立公司。尽管该公司销售额显著增长，研发投资翻了一番，但投资者仍对疫苗销售 的疲软以及在肿瘤战略上的反复感到失望。 智通财经APP获悉，在长达九年任期内始终难以获得投资者的坚定支持后，英国制药巨头葛兰素史克 (GSK.US)首席执行官沃姆斯利(Emma Walmsley)将卸任。该公司表示，曾在包括阿斯利康在内的多家欧 洲大型制药企业任职的现任首席商务官米尔斯(Luke Miels)将于2026年1月1日正式接任首席执行官一 职。 据悉，米尔斯于2017年加入葛兰素史克，目前负责该公司的全球药品与疫苗业务。这位50岁的首席商务 官推动了该公司药物产品组合的扩 ...

Shares of U.K. pharmaceutical giant GSK rallied on Monday after it turned to an insider to become its next CEO. ...

9月29日，英国制药商GSK表示，艾玛·沃尔姆斯利（Emma Walmsley）自明年1月起将不再担任公 司CEO，由GSK现任首席商务官卢克·米尔斯（Luke Miels）接替。米尔斯自2017年加入GSK，目前 负责该公司全球药品和疫苗产品。（第一财经记者 钱童心） ...

GSK announced on Monday that Chief Executive Emma Walmsley will step down after nine years in the role, with current Chief Commercial Officer Luke Miels set to take over on January 1. The transition m... ...